Next, we compared a representative subset of 813 AIEOP-BFM ALL 2000 patients [20] with available TPMT genotype data and no reported history of hepatic SOS to the 13 patients with hepatic SOS under exposure to 6-TG during late-intensification treatment (Protocol II/Protocol III). The gene discussed is TPMT; the disease is acute lymphoblastic leukemia.